Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)
China flag China · Delayed Price · Currency is CNY
27.22
-0.30 (-1.09%)
Nov 17, 2026, 3:00 PM CST

SHA:688076 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
2,1601,9401,6231,033648.03641.71
Other Revenue
2.692.691.990.823.262.16
2,1631,9431,6251,034651.29643.87
Revenue Growth
13.86%19.57%57.21%58.69%1.15%13.58%
Cost of Revenue
1,069809.46575.05444.27307.94306.3
Gross Profit
1,0951,1331,050589.28343.36337.57
Selling, General & Admin
393.39418.66339.13268.23186.98150.49
Research & Development
196.32251.92227.45124.8969.4763.09
Other Operating Expenses
-7.96-5.841.70.029.255.24
Operating Expenses
619.1669.31588.89398.25271.58220.47
Operating Income
475.45464.03460.86191.0471.78117.1
Interest Expense
-83.4-65.46-34.75-16.09-9.26-6.12
Interest & Investment Income
11.612.199.059.1128.548.38
Currency Exchange Gain (Loss)
-4.02-4.028.68-1.381.03-1.58
Other Non Operating Income (Expenses)
-20.081.19-0.58-0.47-0.3-0
EBT Excluding Unusual Items
379.56407.94443.26182.2291.79117.78
Impairment of Goodwill
------1.28
Gain (Loss) on Sale of Investments
8.661.49-2.790.26-1.960.13
Gain (Loss) on Sale of Assets
-8.59-2.2-9.2-15.0618.44-0.97
Asset Writedown
-52.9-14.45-0.33---
Other Unusual Items
-85.35-32.287.575.7114.910.07
Pretax Income
241.38360.49438.5173.13123.16125.73
Income Tax Expense
35.7535.0838.697.670.3916.92
Earnings From Continuing Operations
205.63325.41399.82165.45122.77108.81
Minority Interest in Earnings
17.377.014.57-2.526.346.58
Net Income
223332.42404.39162.94129.11115.39
Net Income to Common
223332.42404.39162.94129.11115.39
Net Income Growth
-55.28%-17.80%148.19%26.20%11.89%-6.52%
Shares Outstanding (Basic)
316314302300296269
Shares Outstanding (Diluted)
316314309300296269
Shares Change
1.87%1.59%2.86%1.28%10.06%19.95%
EPS (Basic)
0.711.061.340.540.440.43
EPS (Diluted)
0.711.061.310.540.440.43
EPS Growth
-56.10%-19.08%141.30%24.60%1.66%-22.07%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
153.12-685.77-690.01-310.43-409.07-52.61
Free Cash Flow Per Share
0.48-2.19-2.23-1.03-1.38-0.20
Dividend Per Share
0.3500.3500.6430.2860.1430.107
Dividend Growth
-38.76%-45.56%125.03%99.93%33.43%-
Gross Margin
50.60%58.34%64.61%57.02%52.72%52.43%
Operating Margin
21.98%23.89%28.36%18.48%11.02%18.19%
Profit Margin
10.31%17.11%24.89%15.77%19.82%17.92%
Free Cash Flow Margin
7.08%-35.30%-42.47%-30.04%-62.81%-8.17%
EBITDA
850.28765.05663.47322.81170.52198.73
EBITDA Margin
39.31%39.38%40.83%31.23%26.18%30.87%
D&A For EBITDA
374.83301.02202.61131.7798.7581.63
EBIT
475.45464.03460.86191.0471.78117.1
EBIT Margin
21.98%23.89%28.36%18.48%11.02%18.19%
Effective Tax Rate
14.81%9.73%8.82%4.43%0.32%13.46%
Revenue as Reported
2,1631,9431,6251,034651.29643.87
Advertising Expenses
-0.181.62---